nach oben

Erschienen in:

26.02.2022 | Original Paper

Women’s Perceptions of HIV- and Sexuality-Related Stigma in Relation to PrEP: Qualitative Findings from the Masibambane Study, Durban, South Africa

verfasst von: S. Bergam, A. D. Harrison, N. Benghu, S. Khumalo, N. Tesfay, T. Exner, L. Miller, C. Dolezal, J. Hanass-Hancock, S. Hoffman

Erschienen in: AIDS and Behavior | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Daily oral pre-exposure prophylaxis (PrEP) offers effective HIV prevention. In South Africa, PrEP is publicly available, but use among young women remains low. We explored young women’s perceptions of PrEP to inform a gender-focused intervention to promote PrEP uptake. Six focus group discussions and eight in-depth interviews exploring perceptions of PrEP were conducted with forty-six women not using PrEP, ages 18–25, from central Durban. Data were thematically analyzed using a team-based consensus approach. The study was conducted among likely PrEP users: women were highly-educated, with 84.8% enrolled in post-secondary education. Qualitative data revealed intersecting social stigmas related to HIV and women’s sexuality. Women feared that daily PrEP pills would be confused with anti-retroviral treatment, creating vulnerability to misplaced HIV stigma. Women also anticipated that taking PrEP could expose them to assumptions of promiscuity from the community. To address these anticipated community-level reactions, women suggested community-facing interventions to reduce the burden on young women considering PrEP. Concerns around PrEP use in this group of urban, educated women reflects layered stigmas that may inhibit future PrEP use. Stigma-reducing strategies, such as media campaigns and educational interventions directed at communities who could benefit from PrEP, should re-frame PrEP as an empowering and responsible choice for young women.

UNAIDS. Global Report on the Global AIDS Epidemic. UNAIDS; 2016.

Abdool Karim SS, Baxter C. HIV incidence rates in adolescent girls and young women in sub-Saharan Africa. Lancet Glob Health. 2019;7(11):e1470–1. https://doi.org/10.1016/S2214-109X(19)30404-8.CrossRef

Wand H, Ramjee G. Targeting the hotspots: investigating spatial and demographic variations in HIV infection in small communities in South Africa. J Int AIDS Soc. 2010;13:41. https://doi.org/10.1186/1758-2652-13-41.CrossRefPubMedPubMedCentral

Birdthistle I, Tanton C, Tomita A, et al. Recent levels and trends in HIV incidence rates among adolescent girls and young women in ten high-prevalence African countries: a systematic review and meta-analysis. Lancet Glob Health. 2019;7(11):e1521–40. https://doi.org/10.1016/S2214-109X(19)30410-3.CrossRefPubMedPubMedCentral

Shisana O, Rehle T, Simbayi LC, et al. Let Our Actions Count: South Africa’s National Strategic Plan for HIV, TB and STIs 2017–2022. 2014. Accessed 15 Oct 2020. https://www.gov.za/sites/default/files/gcis_document/201705/nsp-hiv-tb-stia.pdf

Warren CE, Mayhew SH, Hopkins J. The current status of research on the integration of sexual and reproductive health and HIV services. Stud Fam Plann. 2017;48(2):91–105. https://doi.org/10.1111/sifp.12024.CrossRefPubMedPubMedCentral

George G, Cawood C, Puren A, et al. Evaluating DREAMS HIV prevention interventions targeting adolescent girls and young women in high HIV prevalence districts in South Africa: protocol for a cross-sectional study. BMC Women’s Health. 2020. https://doi.org/10.1186/s12905-019-0875-2. Accessed 2 Feb 2021

Chimbindi N, Birdthistle I, Floyd S, et al. Directed and targeted focused multi-sectoral adolescent HIV prevention: insights from implementation of the ‘DREAMS Partnership’ in rural South Africa. J Int AIDS Soc. 2020. https://doi.org/10.1002/jia2.25575.CrossRefPubMedPubMedCentral

Bekker L-G, Rebe K, Venter F, et al. Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. S Afr J HIV Med. 2016. https://doi.org/10.4102/sajhivmed.v17i1.455.CrossRef

10.

South Africa – PrEPWatch. (2022). https://www.prepwatch.org/country/south-africa/. Accessed 31 Jan 2022

11.

Holmes LE, Kaufman MR, Casella A, et al. Qualitative characterizations of relationships among South African adolescent girls and young women and male partners: implications for engagement across HIV self-testing and pre-exposure prophylaxis prevention cascades. J Int AIDS Soc. 2020;23(Suppl 3):e25521. https://doi.org/10.1002/jia2.25521.CrossRefPubMedPubMedCentral

12.

Jani N, Mathur S, Kahabuka C, Makyao N, Pilgrim N. Relationship dynamics and anticipated stigma: Key considerations for PrEP use among Tanzanian adolescent girls and young women and male partners. PLoS ONE. 2021;16(2):e0246717. https://doi.org/10.1371/journal.pone.0246717.CrossRefPubMedPubMedCentral

13.

Rubincam C, Newman PA, Atujuna M, Bekker L-G. “Why would you promote something that is less percent safer than a condom?”: Perspectives on partially effective HIV prevention technologies among key populations in South Africa. SAHARA J. 2018;15(1):179–86. https://doi.org/10.1080/17290376.2018.1536561.CrossRefPubMedPubMedCentral

14.

Giovenco D, Kuo C, Underhill K, Hoare J, Operario D. “The time has arrived”: perceptions of behavioral adjustments in the context of pre-exposure prophylaxis availability among adolescents in South Africa. AIDS Educ Prev. 2018;30(6):463–73. https://doi.org/10.1521/aeap.2018.30.6.463.CrossRefPubMedPubMedCentral

15.

Scorgie F, Khoza N, Baron D, et al. Disclosure of PrEP use by young women in South Africa and Tanzania: qualitative findings from a demonstration project. Cult Health Sex. 2021;23(2):257–72. https://doi.org/10.1080/13691058.2019.1703041.CrossRefPubMed

16.

Giovenco D, Gill K, Fynn L, et al. Experiences of oral pre-exposure prophylaxis (PrEP) use disclosure among South African adolescent girls and young women and its perceived impact on adherence. PLoS ONE. 2021;16(3):e0248307. https://doi.org/10.1371/journal.pone.0248307.CrossRefPubMedPubMedCentral

17.

Beesham I, Heffron R, Evans S, et al. Exploring the use of oral pre-exposure prophylaxis (PrEP) among women from durban, south africa as part of the hiv prevention package in a clinical trial. AIDS Behav. 2021;25(4):1112–9. https://doi.org/10.1007/s10461-020-03072-0.CrossRefPubMed

18.

Calabrese SK, Underhill K. How stigma surrounding the use of HIV pre-exposure prophylaxis undermines prevention and pleasure: a call to destigmatize “Truvada Whores.” Am J Public Health. 2015;105(10):1960–4. https://doi.org/10.2105/AJPH.2015.302816.CrossRefPubMedPubMedCentral

19.

Armstrong-Mensah E, Hernandez P, Huka M, et al. HIV stigma among women and adolescent girls in South Africa: removing barriers to facilitate prevention. MJA. 2019;3(1):69–74. https://doi.org/10.18689/mja-1000112.CrossRef

20.

Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;15(2):190–7. https://doi.org/10.1007/s11904-018-0385-0.CrossRefPubMedPubMedCentral

21.

Calabrese SK, Dovidio JF, Tekeste M, et al. HIV pre-exposure prophylaxis stigma as a multidimensional barrier to uptake among women who attend planned parenthood. J Acquir Immune Defic Syndr. 2018;79(1):46–53. https://doi.org/10.1097/QAI.0000000000001762.CrossRefPubMedPubMedCentral

22.

Haire BG. Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence—a narrative review. HIV AIDS (Auckl). 2015;7:241–9. https://doi.org/10.2147/HIV.S72419.CrossRef

23.

Emmanuel G, Folayan M, Undelikwe G, et al. Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria. BMC Public Health. 2020;20(1):69. https://doi.org/10.1186/s12889-020-8195-x.CrossRefPubMedPubMedCentral

24.

Maseko B, Hill LM, Phanga T, et al. Perceptions of and interest in HIV pre-exposure prophylaxis use among adolescent girls and young women in Lilongwe, Malawi. PLoS ONE. 2020;15(1):e0226062. https://doi.org/10.1371/journal.pone.0226062.CrossRefPubMedPubMedCentral

25.

Pantelic M, Casale M, Cluver L, Toska E, Moshabela M. Multiple forms of discrimination and internalized stigma compromise retention in HIV care among adolescents: findings from a South African cohort. J Int AIDS Soc. 2020;23(5):e25488. https://doi.org/10.1002/jia2.25488.CrossRefPubMedPubMedCentral

26.

Velloza J, Khoza N, Scorgie F, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23(3):e25463. https://doi.org/10.1002/jia2.25463.CrossRefPubMedPubMedCentral

27.

Harrison A. Hidden love: sexual ideologies and relationship ideals among rural South African adolescents in the context of HIV/AIDS. Cult Health Sex. 2008;10(2):175–89. https://doi.org/10.1080/13691050701775068.CrossRefPubMed

28.

Jewkes R, Morrell R. Gender and sexuality: emerging perspectives from the heterosexual epidemic in South Africa and implications for HIV risk and prevention. J Int AIDS Soc. 2010;13:6. https://doi.org/10.1186/1758-2652-13-6.CrossRefPubMedPubMedCentral

29.

HEAIDS. HIV prevalence and related factors—higher education sector study, South Africa, 2008–2009. Pretoria: Higher Education South Africa; 2010.

30.

Hoffman S, Levasseur M, Mantell JE, et al. Sexual and reproductive health risk behaviors among South African university students: results from a representative campus-wide survey. Afr J AIDS Res. 2017;16(1):1–10. https://doi.org/10.2989/16085906.2016.1259171.CrossRefPubMedPubMedCentral

31.

Baral S, Logie CH, Grosso A, Wirtz AL, Beyrer C. Modified social ecological model: a tool to guide the assessment of the risks and risk contexts of HIV epidemics. BMC Public Health. 2013;13(1):482. https://doi.org/10.1186/1471-2458-13-482.CrossRefPubMedPubMedCentral

32.

Khuzwayo N, Taylor M. Exploring the socio-ecological levels for prevention of sexual risk behaviours of the youth in uMgungundlovu District Municipality, KwaZulu-Natal. Afr J Primary Health Care Fam Med. 2018;10(1):1–8. https://doi.org/10.4102/phcfm.v10i1.1590.CrossRef

33.

Turan JM, Elafros MA, Logie CH, et al. Challenges and opportunities in examining and addressing intersectional stigma and health. BMC Med. 2019;17(1):7. https://doi.org/10.1186/s12916-018-1246-9.CrossRefPubMedPubMedCentral

34.

Larson E, George A, Morgan R, Poteat T. 10 Best resources on… intersectionality with an emphasis on low- and middle-income countries. Health Policy Plan. 2016;31(8):964–9. https://doi.org/10.1093/heapol/czw020.CrossRefPubMed

35.

Durban Population 2020 (Demographics, Maps, Graphs). 2020. Accessed 22 Oct 2020. https://worldpopulationreview.com/world-cities/durban-population

36.

Coovadia H, Jewkes R, Barron P, Sanders D, McIntyre D. The health and health system of South Africa: historical roots of current public health challenges. The Lancet. 2009;374(9692):817–34. https://doi.org/10.1016/S0140-6736(09)60951-X.CrossRef

37.

Bradshaw D, Nannan NN, Pillay-van Wyk V, Laubscher R, Groenewald P, Dorrington RE. Burden of disease in South Africa: Protracted transitions driven by social pathologies. S Afr Med J. 2019;109(11b):69–76. https://doi.org/10.7196/SAMJ.2019.v109i11b.14273.CrossRefPubMed

38.

Kalonji D, Mahomed OH. Health system challenges affecting HIV and tuberculosis integration at primary healthcare clinics in Durban, South Africa. Afr J Prim Health Care Fam Med. 2019. https://doi.org/10.4102/phcfm.v11i1.1831.CrossRefPubMedPubMedCentral

39.

Mbewe L, Govender E. Male partners’ influence on women’s acceptance and use of PrEP products across two high HIV-burdened districts in South Africa. Afr J AIDS Res. 2020;19(2):93–100. https://doi.org/10.2989/16085906.2020.1727932.CrossRefPubMed

40.

Scorgie F, Khoza N, Delany-Moretlwe S, et al. Narrative sexual histories and perceptions of HIV risk among young women taking PrEP in southern Africa: findings from a novel participatory method. Soc Sci Med. 2021;270:113600. https://doi.org/10.1016/j.socscimed.2020.113600.CrossRefPubMed

41.

Govender E, Mansoor L, MacQueen K, Abdool KQ. Secrecy, empowerment and protection: positioning PrEP in KwaZulu-Natal, South Africa. Cult Health Sex. 2017;19(11):1268–85. https://doi.org/10.1080/13691058.2017.1309682.CrossRefPubMed

42.

Stangl AL, Lloyd JK, Brady LM, Holland CE, Baral S. A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come? J Int AIDS Soc. 2013;16:18734. https://doi.org/10.7448/IAS.16.3.18734.CrossRefPubMedPubMedCentral

43.

Potts LC, Henderson C. Evaluation of anti-stigma social marketing campaigns in Ghana and Kenya: time to change global. BMC Public Health. 2021;21:886. https://doi.org/10.1186/s12889-021-10966-8.CrossRefPubMedPubMedCentral

44.

Committee on the Science of Changing Behavioral Health Social Norms; Board on Behavioral, Cognitive, and Sensory Sciences; Division of Behavioral and Social Sciences and Education; National Academies of Sciences, Engineering, and Medicine. Ending Discrimination Against People with Mental and Substance Use Disorders: The Evidence for Stigma Change. Washington (DC): National Academies Press (US); 2016 Aug 3. 4, Approaches to Reducing Stigma

45.

Stangl AL, Earnshaw VA, Logie CH, et al. The Health Stigma and Discrimination Framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas. BMC Med. 2019;17:31. https://doi.org/10.1186/s12916-019-1271-3.CrossRefPubMedPubMedCentral

46.

World Health Organization. European Medicines Agency (EMA) approval of the dapivirine ring for HIV prevention for women in high HIV burden settings. 2020. Accessed 2 Feb 2021. https://www.who.int/news/item/24-07-2020-european-medicines-agency-(ema)-approval-of-the-dapivirine-ring-for-hiv-prevention-for-women-in-high-hiv-burden-settings

47.

Landovitz RJ, Li S, Eron JJ, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472–81. https://doi.org/10.1016/S2352-3018(20)30106-5.CrossRefPubMedPubMedCentral

48.

Montgomery ET, Atujuna M, Krogstad E, et al. The invisible product: Preferences for sustained-release, long-acting pre-exposure prophylaxis to HIV among South African youth. J Acquir Immune Defic Syndr. 2019;80(5):542–50. https://doi.org/10.1097/QAI.0000000000001960.CrossRefPubMedPubMedCentral

49.

Sharma M, Chris A, Chan A, et al. Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocol. BMC Health Serv Res. 2018;18(1):513. https://doi.org/10.1186/s12913-018-3324-2.CrossRefPubMedPubMedCentral

50.

Charest M, Sharma M, Chris A, Schnubb A, Knox DC, et al. Decentralizing PrEP delivery: implementation and dissemination strategies to increase PrEP uptake among MSM in Toronto, Canada. PLoS ONE. 2021;16(3):e0248626. https://doi.org/10.1371/journal.pone.0248626.CrossRefPubMedPubMedCentral

51.

Bassett IV, Govere S, Millham L, et al. Contraception, HIV services, and PrEP in South African hair salons: a qualitative study of owner, stylist, and client perspectives. J Community Health. 2019;44(6):1150–9. https://doi.org/10.1007/s10900-019-00698-7.CrossRefPubMedPubMedCentral

52.

Soto-Torres L, Laborde N, Mathebula F, et al. Male partner influence on women’s HIV prevention trial participation and use of pre-exposure prophylaxis: the importance of “understanding.” Published online April 30, 2015. Accessed 15 Oct 2020. https://www.rti.org/publication/male-partner-influence-womens-hiv-prevention-trial-participation-and-use-pre-exposure

53.

Starks TJ, Payton G, Golub SA, Weinberger CL, Parsons JT. Contextualizing condom use: intimacy interference, stigma, and unprotected sex. J Health Psychol. 2014;19(6):711–20. https://doi.org/10.1177/1359105313478643.CrossRefPubMed

54.

Pilgrim N, Mathur S, Gottert A, Rutenberg N, Pulerwitz J. Building evidence to guide PrEP introduction for adolescent girls and young women. Population Council; 2016. https://doi.org/10.31899/hiv7.1008

55.

Miller L, Morar N, Kapiga S, Ramjee G, Hayes R. Prevention, partners, and power imbalances: women’s views on how male partners affected their adherence to vaginal microbicide gels during HIV prevention trials in Africa. J Acquir Immune Defic Syndr. 2020;85(4):458–65. https://doi.org/10.1097/QAI.0000000000002463.CrossRefPubMedPubMedCentral

56.

Miller L, Morar N, Kapiga S, Ramjee G, Hayes R. Women design their own vaginal microbicide trial: Suggestions on how to improve adherence from former participants of HIV prevention trials. PLoS ONE. 2021;16(1):e0244652. https://doi.org/10.1371/journal.pone.024452.CrossRefPubMedPubMedCentral

57.

Statistics South Africa, ed. Educational Enrolment and Achievement, 2016. Statistics South Africa; 2017.

58.

Bärnighausen KE, Matse S, Kennedy CE, et al. “This is mine, this is for me”: pre-exposure prophylaxis as a source of resilience among women in Eswatini. AIDS. 2019;33(Suppl 1):S45–52. https://doi.org/10.1097/QAD.0000000000002178.CrossRefPubMed

59.

Montgomery ET, Roberts ST, Nel A, et al. Social harms in female-initiated HIV prevention method research: state of the evidence. AIDS. 2019;33(14):2237–44. https://doi.org/10.1097/QAD.0000000000002346.CrossRefPubMed

Titel: Women’s Perceptions of HIV- and Sexuality-Related Stigma in Relation to PrEP: Qualitative Findings from the Masibambane Study, Durban, South Africa
verfasst von: S. Bergam
A. D. Harrison
N. Benghu
S. Khumalo
N. Tesfay
T. Exner
L. Miller
C. Dolezal
J. Hanass-Hancock
S. Hoffman
Publikationsdatum: 26.02.2022
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 9/2022
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-022-03632-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Burden and Correlates of Mental Health Symptoms Among Young Black Gay, Bisexual, and Other Men Who Have Sex with Men Engaged in HIV Care in Atlanta

Predictors of Re-Initiation of Daily Oral Preexposure Prophylaxis Regimen After Discontinuation

Impacts of the COVID-19 Pandemic on People Living with HIV Who Are Members of Vulnerable Groups in Vietnam

Psychological and Emotional Impact of COVID-19 Pandemic on People Living with Chronic Disease: HIV and Cancer

A Syndemic Approach to Explore Factors Associated with Bacterial Vaginosis

HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa